Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04812067Phase 2Completed

A Safety and Efficacy Trial of TTHX1114 in People With CED

Role: lead

NCT04676737Phase 2Completed

TTHX1114(NM141) in Combination With DWEK/DSO

Role: lead

NCT04520321Phase 1Completed

A Phase 1/ Phase 2 Study of TTHX1114(NM141)

Role: lead

NCT05769920Phase 1Completed

Dose Escalation TTHX1114 Ophthalmic Solution

Role: lead

All 4 trials loaded